Home Tags Pharmaceuticals

Tag: Pharmaceuticals

The No Kill Zone: The Other Side of Pharma Acquisitions

In recent years there have been calls for increased scrutiny and enforcement of acquisitions by incumbent pharmaceutical firms of potentially competitive pipeline...

Pay-For-Delay: Who Does the Generic Industry Lobby Represent?

The generic industry lobby, Association for Accessible Medicines (“AAM”), often represents the public interest. In the pharmaceutical industry, it challenges brand drug...

First of All, Do No Harm: New Directions in EU Antitrust...

The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to excessive pharmaceutical...

Rethinking Pharmaceutical Product Reformulations

This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives....
pharma pils image

Invoking the ECJ’s Intel Judgment, the UK Court of Appeal Broadly...

By James Killick, Assimakis Komninos & Aqeel Kadri (White & Case LLP)1   Introduction On March 10, 2020, the UK Court of Appeal upheld the Competition Appeal...

ECJ Ruling on Paroxetine

By James Killick, Marc Israel, Jérémie Jourdan & Aqeel Kadri (White & Case LLP)1 On January 30, 2020 (just sneaking in before Brexit), the European...

Antitrust Enforcement in the Pharmaceuticals and Medical Products Industry in China

B The pharmaceutical and medical products industry in China has seen high levels of antitrust enforcement activity from 2015...
Europills

Paroxetine – The EU Court of Justice Rules on Pay-For-Delay Settlements...

Maria José Schmidt-Kessen (Copenhagen Business School)1   Introduction While we are still awaiting the judgments in the pending appeals on pay-for-delay settlements in Lundbeck2 and Servier,3 the...
pharma pils image

European Court of Justice Paroxetine Ruling Provides Guidance on Patent Settlement...

Jan Blockx (University of Antwerp)1 Introduction Twelve years ago, on January 15, 2008, the European Commission used its power to conduct unannounced inspections in a sector...

US: Celgene settles class action for $55M

US biotech company Celgene has agreed to pay a US$55 million settlement after it was accused of illegally maintaining a monopoly over the market...

News

Antitrust Mix by CPI